Aiding Treatment With 'Sticky Liquid' Drug
Posted on: Wednesday, 28 September 2005, 09:00 CDT
By Emma Brady Health Reporter
Researchers at a Birmingham university are developing a new "sticky liquid" drug which could result in easier treatment for patients suffering oesophageal problems.
A simple liquid formulation which sticks to the oesophageus wall could act as a drug barrier enabling conditions to be treated more effectively.
Scientists from Aston University showcased their research at the British Pharmaceutical Conference being held in Manchester yesterday.
Danielle Russell, of the university's medicines research unit, said: "There are several disorders of oesophageal movement, but, at present, no drug treatment targets the oesophagus directly.
"Bioadhesive formulations allow us to target drugs to a specific site.
"In theory, a good bioadhesive, when swallowed, will have prolonged contact with the inner oesophageal surface, allowing time for the drug to absorb into the relevant site.'
Treating oesophageal problems with drug therapies is often difficult because the body naturally reacts to clear the passage of food.
But Aston University's research team carried out a series of tests to examine how oil-in-water emulsions, designed to mimic the effect of saliva, were retained in the oesophagus.
They found the emulsions did indeed stick to the oesophageal tissue. Scientists then looked at whether adding drugs affected the solution's "stickiness".
Results showed that incorporating the drugs did not impair retention of the emulsions in most cases, and also that they were steadily released over a four-hour period.
Ms Russell said these findings would have several advantages for local drug delivery. She said: "A bioadhesive formulation could reduce the drug dose required because the drug is not diluted in the body fluids, as occurs with a systemic treatment. It also avoids inactivation by gastrointestinal enzymes.
"This could potentially reduce side effects
Source: Birmingham Post; Birmingham (UK)
Related Articles
- FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer
- PhiloGene, Inc. Announces That VEGFb(TM) Has Been Granted Orphan Drug Designation By the FDA for the Treatment of Advanced Melanoma
- Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
- Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
- FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
- Bionovo's Publication Tagged As 'Critical Trial' By Leading Journal: Breast Cancer Research and Treatment
- BlueCross BlueShield Funds $5 Million / 5-Year University at Buffalo Research and Treatment Program for the Severely Obese
- Molecular Insight Pharmaceuticals, Inc. Receives Orphan Drug Designation for Ultratrace(TM) MIBG for Treatment of Neuroendocrine Tumors
- FDA Grants Orphan Drug Designation to ZymoGenetics' IL-21 for Treatment of Melanoma
- University of Maryland Researchers Develop Anthrax Tracking Method
User Comments (0)

RSS Feeds